Akari Therapeutics Plc - American Depositary Shares (AKTX)
1.1300
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 19th, 8:50 AM EDT
Detailed Quote
Previous Close
1.130
Open
1.140
Bid
1.120
Ask
1.130
Day's Range
1.100 - 1.140
52 Week Range
0.8500 - 4.400
Volume
47,364
Market Cap
8.41B
PE Ratio (TTM)
-113.00
EPS (TTM)
-0.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
20,008
Chart
About Akari Therapeutics Plc - American Depositary Shares (AKTX)
Akari Therapeutics is a biotechnology company focused on developing innovative therapies for the treatment of rare and serious diseases. The company is primarily engaged in advancing its pipeline of proprietary drug candidates that target various conditions, including autoimmune disorders and other inflammatory diseases. Akari's approach combines advanced scientific research with a commitment to transforming patient care through novel treatment options. By leveraging its expertise in immunology and drug development, Akari aims to bring potentially life-changing therapies to market, addressing unmet medical needs and improving the quality of life for patients. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Akari Therapeutics, Plc (NASDAQ: AKTX) and Peak Bio Inc. is fair to Akari shareholders.
Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share.
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
